All In Biotech

Drug Trial Radar · NCT04053803

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

An Open-label Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Who Participated in Study IMR-SCD-102

Last checked: Nov 20, 2026Latest source record: Mar 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 22, 2019

Primary completion

Mar 2025

Study completion Mar 2025

Sponsor

Lead sponsor
Imara, Inc.Industry
Sponsor type
Industry
First posted
Aug 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.

Conditions

  • Sickle Cell Disease

Interventions

  • IMR-687Drug

    Oral administration of once daily IMR-687

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with adverse events and serious adverse eventsTime frame: Baseline to Month 49
  2. Proportion of patients with changes in safety cardiac parametersTime frame: Baseline to Month 49
  3. Proportion of patients with changes in clinical laboratory testsTime frame: Baseline to Month 49
  4. Proportion of patients with clinically significant abnormal vital signsTime frame: Baseline to Month 49

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Foundation for Sickle Cell Disease Research

    Hollywood, Florida

  • Baylor Scott & White Medical Center - Temple

    Temple, Texas

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom

  • University College London Hospital NHS Foundation Trust

    London, United Kingdom

  • Guy's and St Thomas Hospital CRF

    London, United Kingdom

  • Royal London Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.